An update on the latest chemical therapies for reflux esophagitis in children

References

• Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American society for pediatric gastroenterology, hepatology, and nutrition and the European society for pediatric gastroenterology, hepatology, and nutrition. J Pediatr Gastroenterol Nutr. 2018;66(3):516–554.
   PubMed Web of Science ®Google Scholar
• Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American society for pediatric gastroenterology, hepatology, and nutrition (NASPGHAN) and the European society for pediatric gastroenterology, hepatology, and nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498–547.
   PubMed Web of Science ®Google Scholar
• Varni JW, Bendo CB, Nurko S, et al. Health-related quality of life in pediatric patients with functional and organic gastrointestinal diseases. J Pediatr. 2015;166(1):85–90.
   PubMed Web of Science ®Google Scholar
• Vandenplas Y. Management of paediatric GERD. Nat Rev Gastroenterol Hepatol. 2014;11(3):147–157.
   PubMed Web of Science ®Google Scholar
• Okimoto E, Ishimura N, Morito Y, et al. Prevalence of gastroesophageal reflux disease in children, adults, and elderly in the same community. J Gastroenterol Hepatol. 2015;30(7):1140–1146.
   PubMed Web of Science ®Google Scholar
• Rybak A, Pesce M, Thapar N, et al. Gastro-esophageal reflux in children. Int J Mol Sci. 2017;18(8).
   PubMed Web of Science ®Google Scholar
• Martigne L, Delaage PH, Thomas-Delecourt F, et al. Prevalence and management of gastroesophageal reflux disease in children and adolescents: a nationwide cross-sectional observational study. Eur J Pediatr. 2012;171(12):1767–1773.
   PubMed Web of Science ®Google Scholar
• Strawczynski H, McKenna RD, Nickerson GH. The behavior of the lower esophageal sphincter in infants and its relationship to gastroesophageal regurgitation. J Pediatr. 1964;64:17–23.
   PubMed Web of Science ®Google Scholar
• Tack J, Pandolfino JE. Pathophysiology of gastroesophageal reflux disease. Gastroenterology. 2018;154(2):277–288.
   PubMed Web of Science ®Google Scholar
• Roman S, Holloway R, Keller J, et al. Validation of criteria for the definition of transient lower esophageal sphincter relaxations using high-resolution manometry. Neurogastroenterol Motil. 2017;29(2):e12920.
   Web of Science ®Google Scholar
• Omari T. Gastro-oesophageal reflux disease in infants and children: new insights, developments and old chestnuts. J Pediatr Gastroenterol Nutr. 2005;41(Suppl 1):S21–S23.
   PubMedGoogle Scholar
• van Wijk MP, Benninga MA, Davidson GP, et al. Small volumes of feed can trigger transient lower esophageal sphincter relaxation and gastroesophageal reflux in the right lateral position in infants. J Pediatr. 2010;156(5):744–748, 8 e1.
   PubMed Web of Science ®Google Scholar
• Hegar B, Dewanti NR, Kadim M, et al. Natural evolution of regurgitation in healthy infants. Acta Paediatr. 2009;98(7):1189–1193.
   PubMed Web of Science ®Google Scholar
• Beaumont H, Bennink RJ, de Jong J, et al. The position of the acid pocket as a major risk factor for acidic reflux in healthy subjects and patients with GORD. Gut. 2010;59(4):441–451.
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, McColl K, Fox M, et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol. 2013;108(7):1058–1064.
   PubMed Web of Science ®Google Scholar
• Rohof WO, Bennink RJ, Boeckxstaens GE. Proton pump inhibitors reduce the size and acidity of the acid pocket in the stomach. Clin Gastroenterol Hepatol. 2014;12(7): 1101–1107. e1.
   PubMed Web of Science ®Google Scholar
• Jo YJ. Proton pump inhibitors reduce the size and acidity of the gastric acid pocket. J Neurogastroenterol Motil. 2015;21(1):133–134.
   PubMed Web of Science ®Google Scholar
• Bardou M, Fortinsky KJ. Safety of medication options for treating pediatric esophagitis. Expert Opin Drug Saf. 2015;14(7):1087–1096.
   PubMed Web of Science ®Google Scholar
• Orenstein SR, McGowan JD. Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux. J Pediatr. 2008;152(3):310–314.
   PubMed Web of Science ®Google Scholar
• Rostas SE, McPherson C. Acid suppression for gastroesophageal reflux disease in infants. Neonatal Netw. 2018;37(1):33–41.
   PubMed Web of Science ®Google Scholar
• McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014;5(2):57–62.
   PubMedGoogle Scholar
• Gold BD, Pilmer B, Kierkus J, et al. Dexlansoprazole for heartburn relief in adolescents with symptomatic, nonerosive gastro-esophageal reflux disease. Dig Dis Sci. 2017;62(11):3059–3068.
   PubMed Web of Science ®Google Scholar
• Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112(6):1798–1810.
   PubMed Web of Science ®Google Scholar
• Tighe M, Afzal NA, Bevan A, et al. Pharmacological treatment of children with gastro-oesophageal reflux. Cochrane Database Syst Rev. 2014;(11):CD008550.
   PubMed Web of Science ®Google Scholar
• Alliet P, Raes M, Bruneel E, et al. Omeprazole in infants with cimetidine-resistant peptic esophagitis. J Pediatr. 1998;132(2):352–354.
   PubMed Web of Science ®Google Scholar
• Hassall E, Israel D, Shepherd R, et al. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International pediatric omeprazole study group. J Pediatr. 2000;137(6):800–807.
   PubMed Web of Science ®Google Scholar
• Litalien C, Theoret Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet. 2005;44(5):441–466.
   PubMed Web of Science ®Google Scholar
• Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–520. e4.
   PubMed Web of Science ®Google Scholar
• van der Pol RJ, Smits MJ, van Wijk MP, et al. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. Pediatrics. 2011;127(5):925–935.
   PubMed Web of Science ®Google Scholar
• Gremse DA, Donnelly JR, Kukulka MJ, et al. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe. Aliment Pharmacol Ther. 2004;19(11):1211–1215.
   PubMed Web of Science ®Google Scholar
• Oshima T, Miwa H. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases. J Neurogastroenterol Motil. 2018;24(3):334.
   PubMed Web of Science ®Google Scholar
• Sakurai Y, Mori Y, Okamoto H, et al. Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects–a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719–730.
   PubMed Web of Science ®Google Scholar
• Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53(6):718–724.
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Gobio-Casali L, Balli F, et al. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Pediatr Gastroenterol Nutr. 1989;8(2):150–156.
   PubMed Web of Science ®Google Scholar
• Simeone D, Caria MC, Miele E, et al. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr. 1997;25(1):51–55.
   PubMed Web of Science ®Google Scholar
• van der Pol R, Langendam M, Benninga M, et al. Efficacy and safety of histamine-2 receptor antagonists. JAMA Pediatr. 2014;168(10):947–954.
   PubMed Web of Science ®Google Scholar
• Orenstein SR, Izadnia F, Khan S. Gastroesophageal reflux disease in children. Gastroenterol Clin North Am. 1999;28(4):947–969.
   PubMed Web of Science ®Google Scholar
• Cucchiara S, Staiano A, Romaniello G, et al. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child. 1984;59(9):842–847.
   PubMed Web of Science ®Google Scholar
• Iacono G, Carroccio A, Montalto G, et al. Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux. Minerva Pediatr. 1991;43(12):797–800.
   PubMedGoogle Scholar
• Tsou VM, Young RM, Hart MH, et al. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics. 1991;87(2):148–151.
   PubMed Web of Science ®Google Scholar
• Zhong NS, Sun T, Zhuo C, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161–171.
   PubMed Web of Science ®Google Scholar
• Savarino E, Zentilin P, Marabotto E, et al. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). Expert Opin Pharmacother. 2017;18(13):1333–1343.
   PubMed Web of Science ®Google Scholar
• Augood C, MacLennan S, Gilbert R, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2003;4:CD002300.
   Google Scholar
• Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol. 2005;59(6):725–729.
   PubMed Web of Science ®Google Scholar
• Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics. 2006;118(2):746–752.
   PubMed Web of Science ®Google Scholar
• Maclennan S, Augood C, Cash-Gibson L, et al. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev. 2010;4:CD002300.
   Google Scholar
• Mauritz FA, Stellato RK, Lwe VH, et al. Laparoscopic antireflux surgery increases health-related quality of life in children with GERD. Surg Endosc. 2017;31(8):3122–3129.
   PubMed Web of Science ®Google Scholar
• Ozdogan S, Tabakci B, Demirel AS, et al. The evaluation of risk factors for recurrent hospitalizations resulting from wheezing attacks in preschool children. Ital J Pediatr. 2015;41:91.
   PubMed Web of Science ®Google Scholar
• Vadlamudi NB, Hitch MC, Dimmitt RA, et al. Baclofen for the treatment of pediatric GERD. J Pediatr Gastroenterol Nutr. 2013;57(6):808–812.
   PubMed Web of Science ®Google Scholar
• Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med. 1989;86(6A):73–76.
   Web of Science ®Google Scholar
• Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr. 1986;5(4):556–559.
   PubMed Web of Science ®Google Scholar
• Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr. 1987;146(2):156–158.
   PubMed Web of Science ®Google Scholar
• Del Piano M, Pagliarulo M, Tari R, et al. Correlation between chronic treatment with proton pump inhibitors and bacterial overgrowth in the stomach: any possible beneficial role for selected lactobacilli? J Clin Gastroenterol. 2014;48(Suppl 1):S40–S46.
   PubMedGoogle Scholar
• Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut. 1987;28(1):96–107.
   PubMed Web of Science ®Google Scholar
• Hafiz RA, Wong C, Paynter S, et al. The risk of community-acquired enteric infection in proton pump inhibitor therapy: systematic review and meta-analysis. Ann Pharmacother. 2018;52(7):613–622.
   PubMed Web of Science ®Google Scholar
• Takagi T, Naito Y, Inoue R, et al. The influence of long-term use of proton pump inhibitors on the gut microbiota: an age-sex-matched case-control study. J Clin Biochem Nutr. 2018;62(1):100–105.
   PubMed Web of Science ®Google Scholar
• Naito Y, Kashiwagi K, Takagi T, et al. Intestinal dysbiosis secondary to proton-pump inhibitor use. Digestion. 2018;97(2):195–204.
   PubMed Web of Science ®Google Scholar
• Sultan N, Nazareno J, Gregor J. Association between proton pump inhibitors and respiratory infections: a systematic review and meta-analysis of clinical trials. Can J Gastroenterol. 2008;22(9):761–766.
   PubMed Web of Science ®Google Scholar
• Merli M, Lucidi C, Di Gregorio V, et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 2015;35(2):362–369.
   PubMed Web of Science ®Google Scholar
• Terrin G, Passariello A, De Curtis M, et al. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics. 2012;129(1):E40–E45.
   PubMed Web of Science ®Google Scholar
• Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. Br J Clin Pharmacol. 2015;80(2):200–208.
   PubMed Web of Science ®Google Scholar
• Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257–267.
   PubMed Web of Science ®Google Scholar
• Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.
   PubMed Web of Science ®Google Scholar
• Herzig SJ, Doughty C, Lahoti S, et al. Acid-suppressive medication use in acute stroke and hospital-acquired pneumonia. Ann Neurol. 2014;76(5):712–718.
   PubMed Web of Science ®Google Scholar
• Zirk-Sadowski J, Masoli JA, Delgado J, et al. Proton-pump inhibitors and long-term risk of community-acquired pneumonia in older adults. J Am Geriatr Soc. 2018;66:1332–1338.
   Web of Science ®Google Scholar
• Johnstone J, Nerenberg K, Loeb M. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 2010;31(11):1165–1177.
   PubMed Web of Science ®Google Scholar
• Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med. 2007;167(9):950–955.
   PubMedGoogle Scholar
• Barkun AN, Bardou M, Pham CQ, et al. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis. Am J Gastroenterol. 2012;107(4):507–520. quiz 21.
   PubMed Web of Science ®Google Scholar
• Lin HC, Xirasagar S, Chung SD, et al. Fewer acute respiratory infection episodes among patients receiving treatment for gastroesophageal reflux disease. PLoS One. 2017;12(2):e0172436.
   PubMed Web of Science ®Google Scholar
• Houben E, Johansson S, Nagy P, et al. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists. Curr Med Res Opin. 2018;34(4):577–583.
   PubMed Web of Science ®Google Scholar
• Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):E817–E820.
   PubMed Web of Science ®Google Scholar
• Winter H, Kum-Nji P, Mahomedy SH, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1-11 months old with symptomatic GERD. J Pediatr Gastroenterol Nutr. 2010;50(6):609–618.
   PubMed Web of Science ®Google Scholar
• Winter H, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months. J Pediatr Gastroenterol Nutr. 2012;55(1):14–20.
   PubMedGoogle Scholar
• Blank ML, Parkin L, Zeng J, et al. Proton Pump Inhibitors and Infant Pneumonia/Other Lower Respiratory Tract Infections: national Nested Case-control Study. J Pediatr Gastroenterol Nutr. 2018;67:335–340.
   PubMed Web of Science ®Google Scholar
• Canani RB, Terrin G. Gastric acidity inhibitors and the risk of intestinal infections. Curr Opin Gastroenterol. 2010;26(1):31–35.
   PubMed Web of Science ®Google Scholar
• Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 2010;31(7):754–759.
   PubMed Web of Science ®Google Scholar
• Doorduyn Y, Van Den Brandhof WE, Van Duynhoven YT, et al. Risk factors for salmonella enteritidis and typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in enteritidis and sandboxes in typhimurium infections. Epidemiol Infect. 2006;134(3):617–626.
   PubMed Web of Science ®Google Scholar
• Guillet R, Stoll BJ, Cotten CM, et al. Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics. 2006;117(2):E137–E142.
   PubMed Web of Science ®Google Scholar
• Ito T, Jensen RT. Association of long-term proton pump inhibitor therapy with bone fractures and effects on absorption of calcium, vitamin B12, iron, and magnesium. Curr Gastroenterol Rep. 2010;12(6):448–457.
   PubMedGoogle Scholar
• Torvinen-Kiiskinen S, Tolppanen AM, Koponen M, et al. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer’s disease-a nested case-control study. Aliment Pharmacol Ther. 2018;47(8):1135–1142.
   PubMed Web of Science ®Google Scholar
• Leontiadis GI, Moayyedi P. Proton pump inhibitors and risk of bone fractures. Curr. Treat. Options Gastroenterol. 2014;12(4):414–423.
   PubMedGoogle Scholar
• Tjon JA, Pe M, Soscia J, et al. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease. Pharmacotherapy. 2013;33(9):956–971.
   PubMed Web of Science ®Google Scholar
• Zhuang RD, Tang LJ, Fang YH, et al. [Clinical analysis of enteral nutrition in 47 children]. Zhonghua Er Ke Za Zhi. 2016;54(7):500–503.
   PubMedGoogle Scholar
• Hassall E, Owen D, Kerr W, et al. Gastric histology in children treated with proton pump inhibitors long term, with emphasis on enterochromaffin cell-like hyperplasia. Aliment Pharmacol Ther. 2011;33(7):829–836.
   PubMed Web of Science ®Google Scholar
• Nelson SP, Chen EH, Syniar GM, et al. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric practice research group. Arch Pediatr Adolesc Med. 1997;151(6):569–572.
   PubMedGoogle Scholar
• Smith CH, Israel DM, Schreiber R, et al. Proton pump inhibitors for irritable infants. Can Fam Physician. 2013;59(2):153–156.
   PubMed Web of Science ®Google Scholar
• Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015;42(5):607–613.
   PubMed Web of Science ®Google Scholar
• Othman F, Crooks CJ, Card TR. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study. BMJ. 2016;355:i5813.
   PubMedGoogle Scholar
• Vieira SCF, Gurgel FM, Leao MZ, et al. Survey on the adherence to the 2009 NASPGHAN-ESPGHAN gastroesophageal reflux guidelines by brazilian paediatricians. J Pediatr Gastroenterol Nutr. 2018;67:E1–E5.
   Web of Science ®Google Scholar